Inherited thrombophilia and pregnancy loss

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 2, 2003, Pages 311-320

  Brenner, Benjamin ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Fetal loss; Low molecular weight heparin; Placenta; Thrombophilia; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; ENOXAPARIN; FIBRIN; HEPARIN; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; FEMALE; FETUS WASTAGE; FIBRIN DEPOSITION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; PLACENTA; PLACENTA CIRCULATION; PREECLAMPSIA; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; VASCULAR DISEASE; INHERITANCE; PREGNANCY COMPLICATION; SPONTANEOUS ABORTION;

EID: 0037642205     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)00097-X     Document Type: Review

References (55)

1. Salafia CM, Minior VK, Pezzullo JC et al. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. American Journal of Obstetrics and Gynecology 1995; 173: 1049-1057.
2. Cook CL & Pridham DD. Recurrent pregnancy loss. Current Opinion in Obstetrics and Gynecology 1995; 7: 357-366.
3. Clifford K, Rai R, Watson H & Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Human Reproduction 1994; 9: 1328-1332.
4. Hatasaka HH. Recurrent miscarriage: epidemiologic factors, definitions, and incidence. Clinical Obstetrics and Gynecology 1994; 37: 625-634.
5. Raziel A, Arieli S, Bukovsky I et al. Investigation of the uterine cavity in recurrent aborters. Fertility and Sterility 1994; 62: 1080-1082.
6. Sanson BJ, Friederich PW, Simioni P et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women. Thrombosis and Haemostasis 1996; 75: 387-388.
7. Raziel A, Komberg Y, Friedler S et al. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. American Journal of Reproductive Immunology 2001; 45: 65-71.
8. Gris JC, Quere I, Monpeyroux F et al. Case-control study of the frequency of thrombophilic disorders in couples with late feotal-loss and no thrombotic antecedent-the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thrombosis and Haemostasis 1999; 81: 891-899.
9. Haverkate F & Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thrombosis and Haemostasis 1995; 73: 151-161.
10. Ridker PM, Miletich JP, Buring JE et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Annals of Internal Medicine 1998; 128: 1000-1003.
11. Rey E, Kahn SR, David M, & Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis by type and timing of fetal loss. Lancet, in press.
12. Grandone E, Margaglione M, Colaizzo D et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thrombosis and Haemostasis 1997; 77: 822-824.
13. Brenner B, Sarig G, Weiner Z et al. Thrombophilic polymorphisms in women with fetal loss. Thrombosis and Haemostasis 1999; 82: 6-9.
14. Sarig G, Hoffman R & Younis J. Thrombophilia is common in women with pregnancy loss and is associated with late pregnancy wastage. Fertility and Sterility 2002; 77: 342-347.
15. Dizon-Townson DS, Kinney S, Branch DW & Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. Journal of Reproductive Immunology 1997; 34: 217-223.
16. Rai R, Shlebak A, Cohen H et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Human Reproduction 2001; 16: 961-965.
17. Roque H, Paidas M, Rebarber A et al. Maternal thrombophilia is associated with second and third trimester fetal death. American Journal of Obstetrics and Gynecology 184; pp S27, abst 0060.
18. Younis JS, Brenner B, Ohel G et al. Activated protein C resistance and factor V Leiden mutation can with first-as well as second-trimester recurrent pregnancy loss. American Journal of Reproductive Immunology 2000; 43: 31-35.
19. Wramsby ML, Sten-Linder M & Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertility and Sterility 2000; 74: 987-991.
20. Meinardi JR, Middeldorp S, de Kam PJ et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Annals of Internal Medicine 1999; 130: 736-739.
21. Tormene D, Simioni P, Prandoni P et al. The risk of fetal loss in family member of probands with factor V Leiden mutation. Thrombosis and Haemostasis 1999; 82: 1237-1239.
22. Eichinger S, Weltermann A, Philipp K et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thrombosis and Haemostasis 1999; 82: 1232-1236.
23. Clark P, Brennand J, Conkie JA et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thrombosis and Haemostasis 1998; 79: 1166-1170.
24. Kjelberg U, Andersson NE, Rosen S et al. APC resistance and other haemostatic variables during pregnancy and puerperium. Thrombosis and Haemostasis 1999; 81: 527-531.
25. Tal J, Schliamser LM, Leibovitz Z et al. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Human Reproduction 1999; 14: 1624-1627.
26. Brenner B, Mandel H, Lanir N et al. Activated protein C resistance can be associated with recurrent fetal loss. British Journal of Haematology 1997; 97: 551-554.
27. Mercier E, Quere I, Mares P & Gris JC. Primary recurrent miscarriages: anti-β2-glycoprotein I igG antibodies induces an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test. Blood 1998; 92: 2993-2994.
28. Souza SS, Ferriani RA, Pontes AG et al. Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion. Human Reproduction 1999; 14: 2448-2450.
29. Martinelli I, Taioli E, Cetin I et al. Mutations in coagulation factors in women with unexplained late fetal loss. New England Journal of Medicine 2000; 343: 1015-1018.
30. de Vries JIP, Dekker GA, Huijgens PC et al. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. British Journal of Obstetrics and Gynaecology 1997; 104: 1248-1254.
31. Goddijn-Wessel TA, Wouters MG, van der Molen EF et al. Hyper-homocysteinemia: a risk factor for placental abruption or infarction. European Journal of Obstetrical Gynecology and Reproductive Biology 1996; 66: 23-29.
32. Coumans AB, Huijgens PC, Jakobs C et al. Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Human Reproduction 1999; 14: 211-214.
33. Nelen WLDM, Blom HJ, Steegers EAP et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertility and Sterility 2000; 74: 1196-1199.
34. Zoller B, Berntsdotter A, Garcia de Frutos P & Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
35. Brenner B, Zivelin A, Lanir N et al. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C deficient newborn with massive thrombosis. Blood 1996; 88: 877-880.
36. Mandel H, Brenner B, Berant M et al. Coexistence of hereditary homocysteinuria and factor V Leiden-effect on thrombosis. New England Journal of Medicine 1996; 334: 763-768.
37. Brenner B, Vulfsons SL, Lanir N & Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden-impact on thrombotic diathesis. British Journal of Haematology 1996; 94: 166-167.
38. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
39. Mousa HA & Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Human Reproduction 2000; 15: 1830-1833.
40. Dizon-Townson DS, Meline L, Nelson LM et al. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. American Journal of Obstetrics and Gynecology 1997; 177: 402-405.
41. Eitzman DT, Westrick RJ, Bi X et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002; 105: 2139-2142.
42. Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilias in women with complications of pregnancy. New England Journal of Medicine 1999; 340: 9-13.
43. Grandone E, Margaglione M, Colaizzo D et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. American Journal of Obstetrics and Gynecology 1998; 179: 1324-1328.
44. Many A, Schreiber I, Rosner S et al. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstetrics and Gynecology 2001; 98: 1041-1044.
45. Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thrombosis and Haemostasis 1999; 81: 668-672.
46. Gris JC, Neveu S, Tailland ML et al. Use of low-molecular weight heparin (Enoxaparin) or of a phenformin-like substance (Moroxydine Chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thrombosis and Haemostasis 1995; 73: 362-367.
47. Brenner B, Hoffman R, Blumenfeld Z et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thrombosis and Haemostasis 2000; 83: 693-697.
48. Nakabayashi M, Yamamoto S & Suzuki K. Analysis of thrombomodulin gene polymorphism in women with severe early-onset preeclampsia. Seminars in Thrombosis and Hemostasis 1999; 25: 473-479.
49. Franchi F, Biguzzi E, Cetin I et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. British Journal of Haematology 2001; 114: 641-646.
50. Glueck CJ, Kupferminc MJ, Fontaine RN et al. Genetic hypofibrinolysis in complicated pregnancies. Obstetrics and Gynecology 2001; 97: 44-48.
51. Yamada H, kato EH, Ebina Y et al. Factor XII deficiency in women with recurrent miscarriage. Gynecologic and Obstetric Investigation 2000; 49: 80-83.
52. Gris JC, Quere I, Dechaud H et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood 2002; 99: 2606-2608.
53. Laude I, Rongieres-Bertrand C, Boyer-Neumann C et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thrombosis and Haemostasis 2001; 85: 18-21.
54. Sarig G, Lanir N, Hoffman R & Brenner B. Protein C global assay in the evaluation of women with idiopathic pregnancy loss. Thrombosis and Haemostasis 2002; 8: 32-36.
55. Isermann B, Hendrickson SB, Hutley K et al. Tissue-restriced expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 2001; 128: 827-838.